ASCO Journals have adopted a format-free submission policy (EZSubmit). New submissions are not scrutinized for compliance with our formatting guidelines (reference style, order of components, figure ...

Real-World Tolerability of Capecitabine and Oxaliplatin in Patients in the United States With Localized Colorectal Cancer Undergoing Curative-Intent Treatment Because of a lack of evidence-based ...

Therapy for Stage IV Non–Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2024.3 ...

Co-Occurrence of Cytogenetic Abnormalities and High-Risk Disease in Newly Diagnosed and Relapsed/Refractory Multiple Myeloma A total of 121 patients (previous ICI-treated cohort, n = 31, and each of ...

Reply to: Treatment Intensification Based on Residual Disease in Elderly Patients With AML ...

Erratum: Comparison of Standard-of-Care Idecabtagene Vicleucel and Ciltacabtagene Autoleucel in Relapsed/Refractory Multiple Myeloma Anti–vascular endothelial growth factor therapy enhances PD-1 ...

Reply to: Enfortumab Vedotin: A Promising Therapy for Head and Neck Cancer With Potential Links to Human Papillomavirus A systematic review of randomized controlled trials of MM that reported testing ...

Circulating tumor DNA (ctDNA) assays are promising tools for the prediction of cancer treatment response. Here, we build a framework for the design of ctDNA biomarkers of therapy response that ...

Toward Functional Biomarkers of Response to Neoadjuvant Oncolytic Virus in Stage II Melanoma: Immune-Förster Resonance Energy Transfer and the Dynamic Tumor Immune Microenvironment This retrospective ...

The use of electronic patient-reported outcome measures (ePROMs) in supportive cancer care can lead to benefits, such as identifying at-risk patients in need of closer monitoring and treatment.

Proposals for the Implementation of a Multidimensional Platform That Allows the Advancement of Oncology Nursing in the Latin American Environment (The INCREASE Proposal) The WHO Global Initiative for ...

How Should We Manage the Impact of Antimicrobial Resistance in Patients With Cancer? An Oncological and Infectious Disease Specialist Point of View ...